Page last updated: 2024-12-08

2'-c-methyluridine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2'-C-methyluridine: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID500903
CHEMBL ID2031681
SCHEMBL ID474592
MeSH IDM0506297

Synonyms (24)

Synonym
2,4(1h,3h)-pyrimidinedione, 1-(2-c-methyl-.beta.-d-ribofuranosyl)-
1-[(2r,3r,4r,5r)-3,4-dihydroxy-5-(hydroxymethyl)-3-methyl-tetrahydrofuran-2-yl]pyrimidine-2,4-dione
2'-methyl uridine
bcx-4018
2'-c-methyluridine
1-[(2r,3r,4r,5r)-3,4-dihydroxy-5-(hydroxymethyl)-3-methyloxolan-2-yl]pyrimidine-2,4-dione
AKOS016015085
1-((2r,3r,4r,5r)-3,4-dihydroxy-5-(hydroxymethyl)-3-methyltetrahydrofuran-2-yl)pyrimidine-2,4(1h,3h)-dione
uridine, 2'-c-methyl-
31448-54-1
CHEMBL2031681
NBKORJKMMVZAOZ-VPCXQMTMSA-N
SCHEMBL474592
2'-c-methyl uridine
DTXSID10333336
mfcd02682960
1-[(2r,3r,4r,5r)-3,4-dihydroxy-5-(hydroxymethyl)-3-methyloxolan-2-yl]-1,2,3,4-tetrahydropyrimidine-2,4-dione
M3153
DS-5292
AMY34564
2'-c-methyl-d-uridine
1-(2-c-methyl--d-ribofuranosyl)uracil
F12660
1-((2r,3r,4r,5r)-3,4-dihydroxy-5-(hydroxymethyl) -3-methyltetrahydrofuran-2-yl)pyrimidine-2,4(1h,3h)-dione
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (8)

Assay IDTitleYearJournalArticle
AID662447Cytotoxicity against human HuH7 cells after 24 hrs by MTS assay2012Bioorganic & medicinal chemistry letters, Jun-15, Volume: 22, Issue:12
Synthesis and characterization of 2'-C-Me branched C-nucleosides as HCV polymerase inhibitors.
AID1191708Antiviral activity against HCV genotype 1a infected in human HuH7 cells by replicon based assay2015Bioorganic & medicinal chemistry letters, Mar-01, Volume: 25, Issue:5
Synthesis and characterization of 1'-C-cyano-2'-fluoro-2'-C-methyl pyrimidine nucleosides as HCV polymerase inhibitors.
AID1191710Inhibition of HCV genotype 1b NS5B RNA dependent RNA polymerase assessed as reduction in triphosphate activity2015Bioorganic & medicinal chemistry letters, Mar-01, Volume: 25, Issue:5
Synthesis and characterization of 1'-C-cyano-2'-fluoro-2'-C-methyl pyrimidine nucleosides as HCV polymerase inhibitors.
AID1463866Antiviral activity against HCV genotype 1b Con1 expressing NS3 protease infected in human Huh-7 cells assessed as reduction in viral RNA replication after 72 hrs by luciferase reporter gene assay2017Bioorganic & medicinal chemistry letters, 09-15, Volume: 27, Issue:18
The discovery of IDX21437: Design, synthesis and antiviral evaluation of 2'-α-chloro-2'-β-C-methyl branched uridine pronucleotides as potent liver-targeted HCV polymerase inhibitors.
AID1463867Cytotoxicity against human HuH7 cells assessed as reduction in cell viability2017Bioorganic & medicinal chemistry letters, 09-15, Volume: 27, Issue:18
The discovery of IDX21437: Design, synthesis and antiviral evaluation of 2'-α-chloro-2'-β-C-methyl branched uridine pronucleotides as potent liver-targeted HCV polymerase inhibitors.
AID1191709Antiviral activity against HCV genotype 1b infected in human HuH7 cells by replicon based assay2015Bioorganic & medicinal chemistry letters, Mar-01, Volume: 25, Issue:5
Synthesis and characterization of 1'-C-cyano-2'-fluoro-2'-C-methyl pyrimidine nucleosides as HCV polymerase inhibitors.
AID662448Inhibition of HCV genotype 1b NS5B after 90 mins2012Bioorganic & medicinal chemistry letters, Jun-15, Volume: 22, Issue:12
Synthesis and characterization of 2'-C-Me branched C-nucleosides as HCV polymerase inhibitors.
AID662446Antiviral activity against HCV genotype 1b infected in human HuH7 cells assessed as cytoprotection after 24 hrs2012Bioorganic & medicinal chemistry letters, Jun-15, Volume: 22, Issue:12
Synthesis and characterization of 2'-C-Me branched C-nucleosides as HCV polymerase inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (8)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (25.00)29.6817
2010's6 (75.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 17.49

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index17.49 (24.57)
Research Supply Index2.20 (2.92)
Research Growth Index4.51 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (17.49)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other8 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]